Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $21.57 Consensus Target Price from Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have earned an average rating of “Buy” from the eight analysts that are covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $21.57.

ZVRA has been the topic of several recent research reports. Canaccord Genuity Group decreased their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Cantor Fitzgerald raised shares of Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, January 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, November 20th.

Insider Transactions at Zevra Therapeutics

In other news, CFO R. Laduane Clifton sold 11,000 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $86,460.00. Following the sale, the chief financial officer now directly owns 51,361 shares in the company, valued at approximately $403,697.46. This trade represents a 17.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Joshua Schafer sold 10,500 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $82,530.00. Following the transaction, the executive vice president now directly owns 29,486 shares in the company, valued at $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 85,773 shares of company stock worth $674,176. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. lifted its holdings in Zevra Therapeutics by 462.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company’s stock valued at $30,441,000 after acquiring an additional 3,001,000 shares during the period. FMR LLC grew its holdings in shares of Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after buying an additional 2,312,384 shares in the last quarter. AIGH Capital Management LLC purchased a new stake in Zevra Therapeutics during the 4th quarter valued at about $6,577,000. Stonepine Capital Management LLC acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at approximately $4,858,000. Finally, Vestal Point Capital LP purchased a new position in Zevra Therapeutics during the third quarter worth approximately $3,644,000. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Stock Up 1.0 %

ZVRA stock opened at $8.07 on Friday. The company has a market cap of $430.78 million, a price-to-earnings ratio of -4.10 and a beta of 2.00. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The business’s 50-day moving average is $8.20 and its two-hundred day moving average is $8.08. Zevra Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $9.76.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.